These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23491460)

  • 41. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC; Hartung HP
    Exp Neurol; 2007 Jan; 203(1):1-4. PubMed ID: 17069803
    [No Abstract]   [Full Text] [Related]  

  • 42. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a.
    Pakdaman H; Fallah A; Sahraian MA; Pakdaman R; Meysamie A
    Neuropediatrics; 2006 Aug; 37(4):257-60. PubMed ID: 17177154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
    Ouallet JC
    Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 45. [Neuroprotective effect of the long-term beta-interferon course in multiple sclerosis: direct and indirect mechanisms].
    Gusev EI; Boĭko AN; Khachanova NV; Demina TL; Davydovskaia MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):70-3. PubMed ID: 16841488
    [No Abstract]   [Full Text] [Related]  

  • 46. [Beta interferon in multiple sclerosis: pharmacological differences].
    Allain H; Bentué-Ferrer D; Schück S; Ruffault A
    Rev Neurol (Paris); 1999; 155 Suppl 2():S24-30. PubMed ID: 10367322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 48. Beta interferons for multiple sclerosis.
    Med Lett Drugs Ther; 2002 Oct; 44(1141):88-9. PubMed ID: 12381969
    [No Abstract]   [Full Text] [Related]  

  • 49. [Therapy adherence to immunomodulator treatment in patients with multiple sclerosis].
    López-Méndez P; Río J; Pérez-Ricart A; Tintoré M; Sastre-Garriga J; Cardona-Pascual I; Gómez-Domingo MR; Montalban X
    Rev Neurol; 2013 Jan; 56(1):8-12. PubMed ID: 23250676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-beta in multiple sclerosis. Can we control its costs?
    Madgwick T
    Pharmacoeconomics; 1997 Oct; 12(4):499-501. PubMed ID: 10174315
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Will public health survive QALYs?
    Heller JG
    Can J Clin Pharmacol; 2002; 9(1):5-6. PubMed ID: 11919640
    [No Abstract]   [Full Text] [Related]  

  • 55. Glatiramer acetate (Copaxone).
    Francis DA
    Int J Clin Pract; 2001; 55(6):394-8. PubMed ID: 11501229
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bioavailability of interferon-beta in patients with multiple sclerosis - fishing for the surrogate.
    Kieseier BC; Hartung HP
    Eur J Neurol; 2010 Mar; 17(3):344-5. PubMed ID: 20050905
    [No Abstract]   [Full Text] [Related]  

  • 57. Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?
    Giovannoni G
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1234. PubMed ID: 15314107
    [No Abstract]   [Full Text] [Related]  

  • 58. Incidence of antibodies in cerebrospinal fluid of patients with multiple sclerosis treated with interferon beta.
    Villa AM; Videla C; Garcea O; Carballal G
    Arq Neuropsiquiatr; 2009 Sep; 67(3B):900-1. PubMed ID: 19838526
    [No Abstract]   [Full Text] [Related]  

  • 59. Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road.
    Goodin DS
    Mult Scler; 2011 Nov; 17(11):1274-5. PubMed ID: 22058084
    [No Abstract]   [Full Text] [Related]  

  • 60. Interferon β-induced acute pancreatitis: About two cases with literature review.
    Aouinti I; Hamza I; Charfi O; Lakhoua G; El Aidli S; Daghfous R; Zaiem A; Kastalli S
    Therapie; 2019 Jun; 74(3):449-450. PubMed ID: 30665738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.